Mycosis fungoides: Disease evolution of the "lion queen" revisited

Giornale Italiano di Dermatologia e Venereologia

Volumn 147, Issue 6, 2012, Pages 523-531

  Quaglino, P ^a   Pimpinelli, N ^b   Berti, E ^c   Calzavara Pinton, P ^d   Lombardo, G A ^e   Rupoli, S ^f   Alaibac, M ^g   Arcaini, L ^h   Bagnato, S ⁱ   Baldo, A ^j   Bottoni, U ^k   Carbone, A ^l   Cestari, R ^m   Clerico, R ⁿ   De Renzo, A ^j   Fava, P ^a   Fierro, M T ^a   Filotico, R ^o   Fimiani, M ^p   Frontani, M ^e   Girgenti, V ^q   Goteri, G ^f   Leali, C ^d   Mamusa, A M ^r   Mariotti, G ^b   Mastrandrea, V ^s   Pellegrini, C ^t   Pennese, E ^u   Pileri, A ^v   Savoia, P ^a   Stelitano, C ^w   Titli, S ^a   Virgili, A ^x   Zichichi, L ^y   Zinzani, P L ^t   Bernengo, M G ^a   more..

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

^e LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^f UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^g UNIVERSITY OF PADOVA   (Italy)

^h UNIVERSITY OF PAVIA   (Italy)

ⁱ Dipartimento di Ostetricia e Ginecologia e Scienze Radiologiche   (Italy)

^j UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^k UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^l CATHOLIC UNIVERSITY   (Italy)

^m La Spezia Hospital   (Italy)

ⁿ SAPIENZA UNIVERSITY OF ROME   (Italy)

^o A Perrino Hospital   (Italy)

^p UNIVERSITY OF SIENA   (Italy)

^q UNIVERSITY OF MILAN   (Italy)

^r Ospedale Oncologico A Businco   (Italy)

^s UNIVERSITY OF BARI   (Italy)

^t UNIVERSITY OF BOLOGNA   (Italy)

^u VITO FAZZI HOSPITAL   (Italy)

^v UNIVERSITY OF BOLOGNA   (Italy)

^w Hospital of Reggio Calabria   (Italy)

^x UNIVERSITY OF FERRARA   (Italy)

^y Trapani Hospital   (Italy)

more..

Author keywords

Dermatitis, exfoliative; Lymphoma, T cell, cutaneous; Mycosis fungoides; Prognosis

Indexed keywords

CANCER STAGING; CLINICAL FEATURE; DISEASE COURSE; ERYTHRODERMA; FOLLOW UP; HUMAN; MYCOSIS FUNGOIDES; NEOPLASM; RARE DISEASE; RELAPSE; REVIEW; WORLD HEALTH ORGANIZATION;

EID: 84874369934     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Lutzner M, Edelson R, Schein P, Green I, Kirkpatrick C, Ahmed A. Cutaneous T-cell lymphomas: the Sézary syndrome, mycosis fungoides, and related disorders. Ann Intern Med 1975;83:534-52.
2. Willemze R, Kerl H, Sterry W, Berti E, Cerroni L, Chimenti S et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997;90:354-71.
3. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH et al. WHO/EORTC classification for cutaneous lymphomas. Blood 2005;105:3768-85.
4. Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: A population-based study of 3884 cases. Blood 2009;113:5064-73.
5. Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol 2007;143:854-9.
6. Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007;110:1713-22.
7. Bunn PA, Lamberg SI. Report of the committee on staging and classification of cutaneous T-cell lymphomas. Cancer Treat Rep 1979;63:725-8.
8. Hwang ST, Janik JE, Jaffe ES, Wilson WH. Mycosis fungoides and Sézary syndrome. Lancet 2008;371:945-57.
9. Parker SR, Bethaney JV. Cutaneous T cell lymphoma-mycosis fungoides and Sezary syndrome: an update. G Ital Dermatol Venereol 2009;144:467-85.
10. Diamandidou E, Colome-Grimmer M, Fayad L, Duvic M, Kurzrock R. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. Blood 1998;92:1150-9.
11. Vergier B, de Muret A, Beylot-Barry M, Vaillant L, Ekouevi D, Chene G et al. Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneous Lymphomas. Blood 2000;95:2212-8.
12. Bernengo MG, Quaglino P, Novelli M, Cappello N, Doveil GC, Lisa F et al. Prognostic factors in Sézary syndrome: a multivariate analysis of clinical, hematological and immunological features. Ann Oncol 1998;9:857-63.
13. Diwan AH, Prieto VG, Herling M, Duvic M, Jones D. Primary Sézary syndrome commonly shows low-grade cytologic atypia and an absence of epidermotropism. Am J Clin Pathol 2005;123:510-5.
14. Prince HM, Whittaker S, Hoppe RT. How I treat Mycosis Fungoides and Sézary syndrome. Blood 2009;114:4337-53.
15. Trautinger F, Knobler R, Willemze R, Peris K, Stadler R, Laroche L et al. EORTC consensus recommendations for the treatment of Mycosis Fungoides/Sézary syndrome. Eur J Cancer 2006;42:1014-30.
16. Foss FM. Enhancing existing approaches to Peripheral T-cell lymphoma. Semin Hematol 2010;47:S8-10.
17. Fierro MT, Doveil GC, Quaglino P, Savoia P, Verrone A, Bemengo MG. Combination of etoposide, idarubicin, cyclophosphamide, vincristine, prednisone and bleomycin (VICOP-B) in the treatment of advanced cutaneous T-cell lymphoma. Dermatology 1997;194:268-72.
18. Dummer R, Assaf C, Bagot M, Gniadecki R, Hauschild A, Knobler R et al. Maintenance therapy in cutaneous T-cell lymphoma: Who, when, what? Eur J Cancer 2007;43:2321-9.
19. Lamberg SI, Green SB, Byar DP, Block JB, Clendenning WE, Epstein EH et al. Status report of 376 mycosis fungoides patients at 4 years: Mycosis Fungoides Cooperative Group. Cancer Treat Rep 1979;63:701-7.
20. Vonderheid EC, Bernengo MG, Burg G, Duvic M, Heald P, Laroche L et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 2002;46:95-106.
21. Vidulich KA, Talpur R, Bassett RL, Duvic M. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma. Int J Dermatol 2009;48:243-52.
22. Scarisbrick JJ, Whittaker S, Evans AV, Fraser-Andrews EA, Child FJ, Dean A et al. Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma. Blood 2001;97:624-30.
23. Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 2010;28:4730-9.
24. Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome:Clinical prognostic factors and risk for disease progression. Arch Dermatol 2003;139:857-66.
25. Zackheim HS, Amin S, Kashani-Sabet M, McMillan A. Prognosis in cutaneous T-cell lymphoma by skin stage:Long-term survival in 489 patients. J Am Acad Dermatol 1999;40:418-25.
26. Toro JR, Stoll HL Jr, Stomper PC, Oseroff AR. Prognostic factors and evaluation of mycosis fungoides and Sézary syndrome. J Am Acad Dermatol 1997;37:58-67.
27. van Doorn R, Van Haselen CW, van Voorst Vader PC, Geerts ML, Heule F, de Rie M et al. Mycosis fungoides:Disease evolution and prognosis of 309 Dutch patients. Arch Dermatol 2000;136:504-10.
28. Diamandidou E, Colome M, Fayad L, Duvic M, Kurzrock R. Prognostic factor analysis in mycosis fungoides/Sézary syndrome. J Am Acad Dermatol 1999;40:914-24.
29. Anadolu RY, Birol A, Sanli H, Erdem C, Türsen U. Mycosis fungoides and Sezary syndrome: therapeutic approach and outcome in 113 patients. Int J Dermatol 2005;44:559-65.
30. Suzuki SY, Ito K, Ito M, Kawai K. Prognosis of 100 Japanese patients with mycosis fungoides and Sézary syndrome. J Dermatol Sci 2010;57:37-43.
31. Quaglino P, Pimpinelli N, Berti E, Calzavara-Pinton P, Lombardo AG, Rupoli S et al. Gruppo Italiano Linfomi Cutanei (GILC). Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides:A multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas. Cancer 2012 (in press).
32. Pimpinelli N, Olsen EA, Santucci M, Vonderheid E, Heffner AC, Stevens S et al. International Society for Cutaneous Lymphoma. Defining early mycosis fungoides. J Am Acad Dermatol 2005;53:1053-63.
33. Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR et al. Clinical end points and response criteria in Mycosis fungoides and Sézary syndrome:a consensus statement of the international society for cutaneous lymphomas, the United States cutaneous lymphoma consortium, and the cutaneous lymphoma task force of the European organisation for research and treatment of cancer. J Clin Oncol 2011;29:2598-607.
34. van Kester MS, Borg MK, Zoutman WH, Out-Luiting JJ, Jansen PM, Dreef EJ et al. A Meta-Analysis of Gene Expression Data Identifies a Molecular Signature Characteristic for Tumor-Stage Mycosis Fungoides. J Invest Dermatol 2012;132:2050-9.
35. Dummer R, Goldinger SM, Cozzio A, French LE, Karpova MB. Cutaneous lymphomas: molecular pathways leading to new drugs. J Invest Dermatol 2011;132:517-25.